SPOTLIGHT -
Perioperative cabozantinib shows promise in metastatic kidney cancer
Perioperative treatment with cabozantinib is feasible with early signs of clinical activity in patients with intermediate- and poor-risk metastatic renal cell carcinoma.
Dr. Parminder Singh discusses bladder-sparing immunotherapy-based approach in MIBC
Singh highlights the phase 3 INTACT trial, which is comparing the safety and efficacy of standard chemoradiation alone versus chemoradiation plus atezolizumab in patients who received TURBT.